Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 335

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 13
Chunk 335
---
 DECEMBER 31, 2024 AND 2023(Currency expressed in United States Dollars (“US$”))(Audited)  Year Ended   December 31,   2024  2023 Cash flows from operating activities:      Net loss $(1,598,342) $(2,629,043)         Adjustments to reconcile net loss to net cash used in operating activities:        Amortization of right-of-use asset  48,983   25,170 Allowances for expected credit losses  883,533   942,800 Recoveries for expected credit losses  (1,689,412)  - Bad debts written off  6,344   6,261 Depreciation of property, plant and equipment  104,160   83,253 Dividend income  (68,130)  (61,409)Fair value gain on investments in equity securities  (69,476)  (306,614)Loss arising from settlement of supplier contract dispute  29,534   - Gain on disposal of investments in equity securities  (38,409)  (7,245) Loss on lease termination  1,384   - Impairment on investments in equity securities  -   6,194 Impairment on property  40,173   - Property, plant and equipment written off  -   18 Stock written off  -   424 Operating loss before working capital changes  (2,349,658)  (1,940,191)         Changes in operating assets and liabilities:        Inventories  (250,854)  (160,387)Trade and other receivables  147,760   650,810 Trade and other payables  204,342   (381,293)Advance payment from customer  95,879   (23,123)Operating lease liabilities  (42,895)  76,620 Tax (liabilities)/recoverable  (38,834)  (44,648)Net cash used in operating activities  (2,234,260)  (1,822,212)         Cash flows from investing activities:        Acquisition of investments in equity securities